Human milk oligosaccharide metabolism enhancement

"Human milk oligosaccharide metabolism enhancement" is not a specific molecule or receptor but rather refers to the process by which certain gut microbes—primarily Bifidobacterium and Lactobacillus species—metabolize human milk oligosaccharides (HMOs) present in breast milk. HMOs are complex carbohydrates composed mainly of D-glucose, D-galactose, N-acetylglucosamine, L-fucose, and N-acetylneuraminic acid. These structures are not digested by the infant but serve as substrates for beneficial bacteria in the gut[1]. The microbial breakdown of HMOs supports colonization by health-promoting bacteria such as bifidobacteria and lactobacilli[3], leading to production of metabolites that protect the intestinal barrier and modulate immune responses. For example, 2′‑fucosyllactose (2′‑FL), a common HMO, can be metabolized by Bifidobacterium infantis to produce pantothenol—a metabolite shown to protect against oxidative stress and colitis in animal models[2]. Enhancement of HMO metabolism is associated with improved degradation/utilization/assimilation pathways in the microbiome and may help prevent diseases like ulcerative colitis through modulation of microbial metabolic functions[2]. However, "human milk oligosaccharide metabolism enhancement" does not refer to a single molecular target or druggable entity; it describes a functional process involving multiple enzymes and transporters within various bacterial species.\n\nBecause this entry does not correspond to an individual protein/receptor/enzyme/transporter typically considered a therapeutic target—and instead describes an entire metabolic pathway/process—it should be flagged as incorrect for structured target databases.

Other names

Human milk oligosaccharide metabolismHMO metabolism enhancementHMO utilization pathways